Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
Share Gainers
THC Global share price surges 11% higher on cannabis production update
Share Gainers
Why this ASX cannabis share jumped 7.5% higher today
Share Market News
Should you still be invested in ASX marijuana shares?
Share Gainers
ASX cannabis shares have started the year on a high
Share Gainers
These 3 ASX small caps are pushing higher today
⏸️ Investing
Canada legalises recreational cannabis use
⏸️ Investing
Why these small cap shares are on the rise today
⏸️ Investing
Why these 4 ASX shares have started the week with a bang
⏸️ Investing
Why these medicinal cannabis companies are charging higher today
⏸️ Investing
Australian medicinal cannabis industry Q1 update
⏸️ Investing
Medicinal cannabis update: Here's what you missed
⏸️ Investing
Can Australians get rich quick in the pot stock sector?
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
18 Apr 2024 | $0.72 | $0.01 | 1.41% | 6,518 | $0.72 | $0.72 | $0.71 |
17 Apr 2024 | $0.71 | $-0.01 | -1.39% | 7,495 | $0.72 | $0.72 | $0.71 |
16 Apr 2024 | $0.72 | $0.01 | 1.41% | 515 | $0.73 | $0.73 | $0.72 |
15 Apr 2024 | $0.71 | $0.02 | 2.90% | 3,516 | $0.69 | $0.75 | $0.69 |
12 Apr 2024 | $0.69 | $0.00 | 0.00% | 1,386 | $0.69 | $0.72 | $0.69 |
11 Apr 2024 | $0.69 | $-0.01 | -1.43% | 1,968 | $0.70 | $0.71 | $0.69 |
10 Apr 2024 | $0.70 | $0.00 | 0.00% | 1,942 | $0.69 | $0.70 | $0.69 |
09 Apr 2024 | $0.70 | $0.01 | 1.44% | 3,220 | $0.70 | $0.70 | $0.70 |
08 Apr 2024 | $0.70 | $-0.01 | -1.43% | 957 | $0.69 | $0.70 | $0.69 |
05 Apr 2024 | $0.70 | $0.00 | 0.00% | 2,359 | $0.70 | $0.70 | $0.70 |
04 Apr 2024 | $0.70 | $0.00 | 0.00% | 635 | $0.70 | $0.70 | $0.70 |
03 Apr 2024 | $0.70 | $0.01 | 1.46% | 7,408 | $0.69 | $0.70 | $0.69 |
02 Apr 2024 | $0.69 | $-0.01 | -1.43% | 3,796 | $0.70 | $0.70 | $0.68 |
28 Mar 2024 | $0.70 | $-0.03 | -4.11% | 2,485 | $0.73 | $0.73 | $0.70 |
27 Mar 2024 | $0.73 | $0.01 | 1.39% | 609 | $0.72 | $0.73 | $0.72 |
26 Mar 2024 | $0.72 | $0.02 | 2.86% | 2,685 | $0.70 | $0.72 | $0.70 |
25 Mar 2024 | $0.70 | $0.01 | 1.45% | 3,644 | $0.70 | $0.70 | $0.70 |
22 Mar 2024 | $0.69 | $-0.04 | -5.52% | 5,156 | $0.70 | $0.70 | $0.69 |
21 Mar 2024 | $0.73 | $0.03 | 4.29% | 1,683 | $0.70 | $0.73 | $0.70 |
20 Mar 2024 | $0.70 | $0.01 | 1.45% | 370 | $0.69 | $0.70 | $0.69 |
19 Mar 2024 | $0.69 | $0.00 | 0.00% | 3,120 | $0.69 | $0.69 | $0.69 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
24 Nov 2023 | Timothy (Tim) Slate | Issued | 100,000 | $47,335 |
Director remuneration.
|
24 Nov 2023 | Oludare Odumosu | Issued | 200,000 | $94,669 |
Director remuneration. As per announcement on 24-11-2023
|
24 Nov 2023 | Osagie Imasogie | Issued | 150,000 | $71,002 |
Director remuneration.
|
24 Nov 2023 | Greg Blake | Issued | 175,000 | $82,836 |
Director remuneration.
|
24 Nov 2023 | Donna O'Donnell | Issued | 145,000 | $91,430 |
Director remuneration.
|
11 Sep 2023 | Greg Blake | Expiry | 114,290 | $113,147 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organizations.
|
Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.
|
Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialization of several products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch pathway and commercialization planning for both domestic and international markets.
|
Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Mr Malik Majeed | 1,134,644 | 10.00% |
Quincy Street Capital Llc | 456,622 | 4.02% |
Mr Zoltan Kerekes | 393,168 | 3.46% |
Osagie Imasogie | 393,168 | 3.47% |
Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
Ms Lisa Gray | 381,988 | 3.37% |
Mera I Llc\C | 332,479 | 2.93% |
Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
Mr Steve Shapiro | 302,571 | 2.67% |
Mara Gordon | 252,242 | 2.22% |
Ubs Nominees Pty Ltd | 160,689 | 1.42% |
Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
Dr Chanda Latrice Macias | 146,479 | 1.29% |
Mera Ii Llc\C | 133,372 | 1.18% |
Citicorp Nominees Pty Limited | 132,506 | 1.17% |
Oludare Odumosu | 131,766 | 1.16% |
Muller Ct Pty Ltd <Muller Super Fund A/C> | 118,107 | 1.04% |
Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
Geers Egag Llc | 85,715 | 0.76% |